In fact, CCL11/CCR3 have been implicated as diagnostic biomarkers in gastric cancer [9], prostate cancer [11], and ovarian cancer [31], and as prognostic biomarkers in renal cell carcinoma [12], lymphoma [5] and ovarian cancer [32]. This evidence concerns the gene CCL11 and ovarian cancer.